Shuttle Pharmaceuticals

SHPH

Market cap $3.07M

Initial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury Assets Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current Report on Form-8-K dated May 7, 2026 (the "Closing 8-K"), filed with the U.S. Securities and Exchange Commission (the "SEC"), the Closing was completed on May 6, 2026.

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced it served as exclusive M&A advisor and placement agent in connection with the successful closing of Shuttle Pharmaceuticals Holdings, Inc.'s (NASDAQ: SHPH) acquisition of United Dogecoin Inc. (“United Dogecoin” or the “Company”), a Dogecoin mining company driven by industry experts.

The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrate Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle.

The combination and related financing is expected to result in the largest publicly listed Dogecoin mining company based on percentage of the global hashrate Gaithersburg, Maryland--(Newsfile Corp. - April 30, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts. United Dogecoin will be merged into a wholly owned subsidiary of Shuttle.

Gaithersburg, Maryland--(Newsfile Corp. - March 27, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development. The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates.

Gaithersburg, Maryland--(Newsfile Corp. - March 26, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced a major advancement to its molecule.ai platform, significantly expanding its capabilities in therapeutic discovery and positioning the Company at the forefront of AI-driven drug development. The latest release introduces new models that enable users to more effectively evaluate, prioritize, and advance therapeutic candidates.

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million public offering by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (“Shuttle Pharmaceuticals” or the “Company”), the owner of Molecule.ai, an artificial intelligence (“AI”) driven platform for molecular discovery and early-stage drug development.

Gaithersburg, Maryland--(Newsfile Corp. - March 6, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, today announced that it has entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common stock, in a public offering, for aggregate gross proceeds of approximately $3,500,000, before deducting placement agent fees and other offering expenses. The offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions.

Gaithersburg, Maryland--(Newsfile Corp. - January 13, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), applauds the state of Utah which has become the first state in the United States to allow artificial intelligence systems to authorize prescription refills without direct physician involvement — a regulatory first that signals how AI is beginning to reduce healthcare costs, eliminate delays, and expand access to care. The pilot program, launched through Utah's Office of Artificial Intelligence Policy and powered by Doctronic, allows AI to refill certain commonly prescribed medications for chronic conditions.

Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.